دورية أكاديمية
أعرض في EDS

Intermittent ethanol exposure increases long-lasting behavioral and neurochemical effects of MDMA in adolescent mice.

التفاصيل البيبلوغرافية
العنوان: Intermittent ethanol exposure increases long-lasting behavioral and neurochemical effects of MDMA in adolescent mice.
المؤلفون: Rodríguez-Arias M; Unidad de Investigación Psicobiología de las Drogodependencias, Departamento de Psicobiología, Facultad de Psicología, Universitat de Valencia, Avda. Blasco Ibáñez 21, 46010 Valencia, Spain. marta.rodriguez@uv.es, Maldonado C, Vidal-Infer A, Guerri C, Aguilar MA, Miñarro J
المصدر: Psychopharmacology [Psychopharmacology (Berl)] 2011 Nov; Vol. 218 (2), pp. 429-42. Date of Electronic Publication: 2011 May 10.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2072 (Electronic) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin, New York, Springer-Verlag.
مواضيع طبية MeSH: Behavior, Animal/*drug effects , Ethanol/*toxicity , Hallucinogens/*toxicity , N-Methyl-3,4-methylenedioxyamphetamine/*toxicity, Age Factors ; Animals ; Anxiety/etiology ; Brain/drug effects ; Brain/metabolism ; Dopamine/metabolism ; Dose-Response Relationship, Drug ; Drug Interactions ; Ethanol/administration & dosage ; Hallucinogens/administration & dosage ; Male ; Maze Learning/drug effects ; Mice ; Motor Activity/drug effects ; N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage ; Social Behavior
مستخلص: Rationale: Heavy binge drinking is increasingly frequent among adolescents, while ethanol (EtOH) is often used in combination with 3,4-methylenedioxymethamphetamine (MDMA).
Objectives: The long-lasting effects of intermittent exposure to EtOH and MDMA during adolescence on motor activity, anxiety, and social behavior were evaluated in adult mice. The concentration of brain monoamines in the striatum, cortex, and hippocampus was measured following the behavioral test.
Methods: Adolescent OF1 mice were exposed to ethanol (1.25 g/kg) on two consecutive days at 48-h intervals over a 14-day period (from PND 29 to 42). A total of eight injections of MDMA (10 or 20 mg/kg) were administered twice daily at 4-h intervals over two consecutive days, and this schedule was repeated 6 days later (PND 33, 34, 41, and 42). Behavioral tests and analysis of brain monoamines took place on PND 64 to 67.
Results: Exposure to MDMA during adolescence increased the anxiogenic response in the elevated plus maze, with adult mice spending less time in the open arms of the maze and exhibiting lower concentrations of DA in the striatum. A pattern of ethanol administration modeling binge drinking during adolescence enhanced these effects and undermined the hyperthermic response induced by MDMA. Passive avoidance was affected only when EtOH was administered alone.
Conclusions: Juvenile administration of MDMA and alcohol was found to cause a decrease in monoamine levels in adulthood, as well as changes in social interaction behaviors, locomotor activity, increase measures of anxiety in the elevated plus maze (EPM), and decrease step-through latencies in passive avoidance test.
References: Nature. 1970 Jun 6;226(5249):967-8. (PMID: 5463060)
Psychopharmacology (Berl). 1992;107(2-3):144-59. (PMID: 1615119)
Toxicology. 2008 Oct 30;252(1-3):64-71. (PMID: 18761051)
Neurotox Res. 2002 Jun;4(4):327-35. (PMID: 12829422)
Hum Psychopharmacol. 2006 Jun;21(4):255-63. (PMID: 16783813)
Alcohol Clin Exp Res. 2000 Nov;24(11):1712-23. (PMID: 11104119)
Int J Neuropsychopharmacol. 2009 Jul;12(6):749-59. (PMID: 19046482)
Psychopharmacology (Berl). 2007 Jul;192(4):555-69. (PMID: 17345065)
Curr Pharm Biotechnol. 2010 Aug;11(5):460-9. (PMID: 20420572)
Int J Neuropsychopharmacol. 2008 Sep;11(6):743-63. (PMID: 18248690)
J Pharmacol Exp Ther. 1994 Aug;270(2):752-60. (PMID: 8071868)
Alcohol Alcohol. 2003 May-Jun;38(3):243-8. (PMID: 12711659)
Neuropsychopharmacology. 2007 Aug;32(8):1750-9. (PMID: 17299518)
BMJ. 1992 Jul 4;305(6844):5-6. (PMID: 1353390)
J Pharmacol Exp Ther. 2007 Sep;322(3):1003-12. (PMID: 17526809)
Pharmacol Biochem Behav. 2006 May;84(1):162-8. (PMID: 16750260)
Pharmacol Biochem Behav. 1986 Mar;24(3):525-9. (PMID: 2871560)
J Stud Alcohol Drugs. 2008 Jan;69(1):100-11. (PMID: 18080070)
Pharmacol Ther. 1988;36(2-3):335-427. (PMID: 3279433)
Eur J Pharmacol. 2007 Oct 1;571(2-3):152-5. (PMID: 17617399)
Subst Use Misuse. 2006;41(8):1095-109. (PMID: 16798678)
Exp Neurol. 2000 Feb;161(2):704-13. (PMID: 10686089)
Pharmacol Biochem Behav. 2005 Sep;82(1):190-9. (PMID: 16154187)
Neuropsychopharmacology. 2005 Oct;30(10):1870-82. (PMID: 15785779)
Neuropsychopharmacology. 2005 Jul;30(7):1312-23. (PMID: 15688085)
Neurobiol Dis. 2011 Apr;42(1):85-98. (PMID: 21220020)
Addiction. 2001 Jul;96(7):1035-47. (PMID: 11440614)
Alcohol. 2004 Oct-Nov;34(2-3):285-9. (PMID: 15902924)
Eur J Neurosci. 2007 Jan;25(2):541-50. (PMID: 17284196)
Physiol Behav. 1986;37(5):689-94. (PMID: 3774901)
Br J Pharmacol. 2001 Dec;134(8):1711-23. (PMID: 11739248)
Genes Brain Behav. 2010 Oct;9(7):712-21. (PMID: 20528954)
Psychopharmacology (Berl). 2009 Jun;204(2):375-8. (PMID: 19139850)
Recent Dev Alcohol. 2005;17:161-76. (PMID: 15789865)
Pharmacol Biochem Behav. 1997 May-Jun;57(1-2):127-36. (PMID: 9164563)
Eur J Pharmacol. 2008 Aug 20;590(1-3):204-11. (PMID: 18585379)
Psychopharmacology (Berl). 2010 Jan;207(4):671-9. (PMID: 19841904)
Eur Neuropsychopharmacol. 1998 May;8(2):95-103. (PMID: 9619687)
Toxicol Lett. 2009 Jul 24;188(2):167-72. (PMID: 19446252)
Behav Processes. 1981 Dec;6(4):319-27. (PMID: 24925864)
Lancet. 1991 Nov 23;338(8778):1335. (PMID: 1682711)
Alcohol Clin Exp Res. 2008 Mar;32(3):375-85. (PMID: 18241320)
J Stud Alcohol. 2004 Mar;65(2):204-12. (PMID: 15151351)
J Psychopharmacol. 2006 Mar;20(2):194-210. (PMID: 16510478)
Ann N Y Acad Sci. 2006 Aug;1074:643-9. (PMID: 17105959)
Brain Res. 1988 Mar 22;444(2):340-5. (PMID: 2834024)
J Pharmacol Exp Ther. 2002 Jan;300(1):236-44. (PMID: 11752122)
J Stud Alcohol Drugs. 2008 Mar;69(2):308-12. (PMID: 18299773)
Psychopharmacology (Berl). 2004 May;173(3-4):278-86. (PMID: 14735292)
Psychopharmacology (Berl). 2008 Mar;197(1):67-82. (PMID: 18040665)
Alcohol Clin Exp Res. 2006 Jun;30(6):1006-10. (PMID: 16737459)
J Psychopharmacol. 2010 Feb;24(2):275-9. (PMID: 19282425)
المشرفين على المادة: 0 (Hallucinogens)
3K9958V90M (Ethanol)
KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
VTD58H1Z2X (Dopamine)
تواريخ الأحداث: Date Created: 20110511 Date Completed: 20120221 Latest Revision: 20211020
رمز التحديث: 20231215
DOI: 10.1007/s00213-011-2329-x
PMID: 21556804
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-2072
DOI:10.1007/s00213-011-2329-x